The company said it has seen progress in efforts to get FDA approval for its tissue and liquid biopsy tests as data continues to accumulate for pan-cancer utility.
The grant recipients will receive up to $5 million each and are led by scientists at institutions including Harvard Medical School and the Cleveland Clinic.
The researchers said that they have demonstrated an approach that skirts a bottleneck and enables building pathology support systems from large datasets.
MSK-ACCESS sequences 129 cancer-associated genes selected from the MSK-IMPACT assay and is designed to detect gene alterations in cfDNA specimen.
Researchers in Nigeria are developing a handheld diagnostic device for identifying high-risk colorectal cancer patients in low-resource environments.
The center received a response to its initial submission to the NY State Department of Health in February and will re-submit by the end of this month.
With deep learning software running on a supercomputer, Paige.AI is developing pathology technology that learns from large-scale digital image datasets.
Elypta anticipates launching a test to conduct surveillance for recurrence of renal cell carcinoma in patients that have undergone surgery.
The researchers believe using cerebral spinal fluid will enable them to identify brain tumors with a higher sensitivity than with blood samples.
MSK researchers showed that high TMB may be associated with improved survival across tumor types, but the cut-offs for high and low status will vary based on histology.